Vidya Ramakrishnan

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease

Edmond Teng, Paul T. Manser, Karen Pickthorn et al. · JAMA Neurology · 2022 · 191 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

Cecília Monteiro, Balázs István Tóth, Flávia Brunstein et al. · Neurology · 2023 · 108 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

Vidya Ramakrishnan, Christina Friedrich, Colleen M. Witt et al. · CPT Pharmacometrics & Systems Pharmacology · 2022 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB

Samira Jamalian, Michael Dolton, Pascal Chanu et al. · CPT Pharmacometrics & Systems Pharmacology · 2023 · 19 citations · Full text

Medicine, Biostatistics, Neurology +17

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Stephen Schauer, Balázs István Tóth, Julie Lee et al. · Alzheimer s & Dementia · 2024 · 13 citations · Full text

Life Sciences, Neurology, Neuroscience +17